Rigel Pharmaceuticals traded at $1.59 this Wednesday August 17th, increasing $0.03 or 1.92 percent since the previous trading session. Looking back, over the last four weeks, Rigel Pharmaceuticals gained 29.27 percent. Over the last 12 months, its price fell by 54.57 percent. Looking ahead, we forecast Rigel Pharmaceuticals to be priced at 1.50 by the end of this quarter and at 1.37 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Daiichi Sankyo 4,084.00 -51.00 -1.23% 66.29%
Acura Pharmaceuticals 0.07 -0.03 -30.00% -89.06%
Agenus 2.79 -0.19 -6.38% -53.58%
Applied Genetic Technologies 0.44 -0.04 -7.81% -86.74%
Amgen 250.58 -2.57 -1.02% 10.47%
Anika Therapeutics 22.86 -0.27 -1.17% -45.05%
Arrowhead Research 45.88 -1.75 -3.67% -23.24%
AstraZeneca 11,002.00 34.00 0.31% 26.00%
Astrazeneca 66.42 -0.32 -0.48% 11.74%
BioMarin Pharmaceutical 94.84 -0.19 -0.20% 25.55%
Bristol-Myers Squibb 74.56 0.43 0.58% 8.83%
ChemoCentryx 50.78 -0.08 -0.16% 266.38%
Celldex Therapeutics 36.73 -0.59 -1.58% -17.76%
Halozyme Therapeutics 43.41 -1.07 -2.41% 9.84%
Heron Therapeutics 5.11 -0.26 -4.84% -50.63%
Immunogen 5.78 -0.16 -2.69% 11.80%
Ionis Pharmaceuticals 43.88 -0.44 -0.99% 15.38%
Karyopharm Therapeutics 5.30 -0.19 -3.46% 12.05%
Ligand Pharmaceuticals 106.04 -1.52 -1.41% 0.70%
Eli Lilly 316.82 6.51 2.10% 17.17%
MacroGenics 4.49 -0.02 -0.44% -79.61%
Neurocrine Biosciences 104.94 -1.17 -1.10% 14.31%
Pfizer 49.27 -0.59 -1.18% -0.08%
Ultragenyx Pharmaceutical 47.25 -2.06 -4.18% -42.35%
Regeneron Pharmaceuticals 636.34 -12.36 -1.91% -2.94%
Rigel Pharmaceuticals 1.59 0.03 1.92% -54.57%
Sangamo BioSciences 5.89 -0.20 -3.28% -37.47%
Veracyte 22.58 -1.55 -6.42% -39.04%
Intrexon 2.28 -0.13 -5.39% -60.42%

Indexes Price Day Year
USND 12938 -164.43 -1.25% -10.93%
US2000 1987 -33.22 -1.64% -7.94%

Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The Company's research focuses on signaling pathways that are critical to disease mechanisms. The Company's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its clinical program, Fostamatinib is being studied in a Phase III trial for the treatment of warm autoimmune hemolytic anemia (wAIHA). The Company's other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIP1) inhibitor program.